TY - JOUR
T1 - Targeting the IGF1 axis in cancer proliferation
AU - Bruchim, Ilan
AU - Attias, Zohar
AU - Werner, Haim
N1 - Funding Information:
The authors’ work is supported by grants from the Insulin-Dependent Diabetes Trust (IDDT, UK), the US-Israel Binational Science Foundation (BSF, Grant 2003341), and the Israel Cancer Research Fund (ICRF, New York). I Bruchim wishes to thank the Israel Cancer Research Fund (Montreal, Canada) for their generous support.
PY - 2009/10
Y1 - 2009/10
N2 - The IGF network of ligands, cell-surface receptors and IGF-binding proteins has important roles at multiple levels, including the cellular, organ and organism levels. The IGF system mediates growth, differentiation and developmental processes, and is also involved in various metabolic activities. Dysregulation of IGF system expression and action is linked to diverse pathologies, ranging from growth deficits to cancer development. Targeting of the IGF axis emerged in recent years as a promising therapeutic approach in conditions in which the IGF system is involved. Specific IGF1 receptor (IGF1R) targeting, in particular, produced the best experimental and clinical results so far, and generated significant optimism in the field. This review provides a basic analysis of the role of the IGF1R in cancer biology and explores the functional interactions between the IGF signaling pathways and various cancer genes (e.g., oncogenes, tumor suppressors). In addition, we review a number of specific malignancies in which the IGF system is involved and summarize recent data on preclinical and clinical studies employing IGF1R-targeted modalities.
AB - The IGF network of ligands, cell-surface receptors and IGF-binding proteins has important roles at multiple levels, including the cellular, organ and organism levels. The IGF system mediates growth, differentiation and developmental processes, and is also involved in various metabolic activities. Dysregulation of IGF system expression and action is linked to diverse pathologies, ranging from growth deficits to cancer development. Targeting of the IGF axis emerged in recent years as a promising therapeutic approach in conditions in which the IGF system is involved. Specific IGF1 receptor (IGF1R) targeting, in particular, produced the best experimental and clinical results so far, and generated significant optimism in the field. This review provides a basic analysis of the role of the IGF1R in cancer biology and explores the functional interactions between the IGF signaling pathways and various cancer genes (e.g., oncogenes, tumor suppressors). In addition, we review a number of specific malignancies in which the IGF system is involved and summarize recent data on preclinical and clinical studies employing IGF1R-targeted modalities.
KW - IGF-1 receptor (IGF1R)
KW - Insulin-like growth factors (IGF)
KW - Monoclonal antibodies
KW - Targeted therapy
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=70349397421&partnerID=8YFLogxK
U2 - 10.1517/14728220903201702
DO - 10.1517/14728220903201702
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:70349397421
SN - 1472-8222
VL - 13
SP - 1179
EP - 1192
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 10
ER -
